Nuvectis Pharma Inc.
Organization details
- Legal name
- Nuvectis Pharma Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Fort LEE
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NVCT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001875558
- EIN
- 86-2405608
Board of directors
-
James F. Oliviero III · DirectorSince 2023
-
Juan Sanchez · DirectorSince 2025
-
Kenneth Hoberman · DirectorSince 2023
-
Matthew L. Kaplan · DirectorSince 2023
-
Ron Bentsur · Director · Chairman & CEOSince 2023
Chief executives
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.5%
Board connections
2 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Beyond Air Inc. Same sectorvia Ron Bentsur
-
TG Therapeutics Inc. Same sectorvia Kenneth Hoberman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,166,000
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Carson Michael J. Officer (Vice President, Finance) | Grant or award | +30,000 | — | — |
| Jun 30, 2026 | Ron Bentsur Director, Officer (Chairman & CEO), 10% owner | Open-market purchase | +12,500 | $20.00 | $250,000 |
| Jun 30, 2026 | Mosseri Marlio Charles 10% owner | Open-market purchase | +50,000 | $18.32 | $916,000 |
| Jun 11, 2026 | Kenneth Hoberman Director | Grant or award | +35,000 | — | — |
| Jun 11, 2026 | James F. Oliviero III Director | Grant or award | +35,000 | — | — |
| Jun 11, 2026 | Juan Sanchez Director | Grant or award | +35,000 | — | — |
| Jun 11, 2026 | Matthew L. Kaplan Director | Grant or award | +35,000 | — | — |
| Jan 6, 2026 | Shemesh Shay Officer (Chief Dev. & Ops. Officer) | Grant or award | +150,000 | — | — |
| Jan 6, 2026 | Ron Bentsur Director, Officer (Chairman & CEO), 10% owner | Grant or award | +150,000 | — | — |
| Jan 6, 2026 | Poradosu Enrique Officer (Chief Science & Business Off) | Grant or award | +150,000 | — | — |
| Jan 6, 2026 | Carson Michael J. Officer (Vice President, Finance) | Grant or award | +61,200 | — | — |
| Nov 5, 2025 | Ron Bentsur Director, Officer (Chairman & CEO), 10% owner | Open-market purchase | +5,000 | $5.72 | $28,600 |
| Nov 5, 2025 | Juan Sanchez Director | Open-market purchase | +13,000 | $5.79 | $75,270 |
| Nov 5, 2025 | Matthew L. Kaplan Director | Open-market purchase | +11,000 | $5.84 | $64,240 |
| Oct 27, 2025 | Mosseri Marlio Charles 10% owner | Open-market purchase | +72,836 | $6.28 | $457,410 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Nuvectis Pharma Inc.
Who is the CEO of Nuvectis Pharma Inc.?
Ron Bentsur is Nuvectis Pharma Inc.'s Chairman & CEO.
How many directors are on Nuvectis Pharma Inc.'s board?
Nuvectis Pharma Inc.'s board has 5 directors: James F. Oliviero III, Juan Sanchez, Kenneth Hoberman, Matthew L. Kaplan and Ron Bentsur.
Are Nuvectis Pharma Inc. insiders buying or selling shares?
Over the last 12 months, Nuvectis Pharma Inc. insiders bought $1.2 million of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="nuvectis-pharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.